Participants aged 65 years and older in the phase 3 trials
Hepatic and renal impairment: regulatory expectation for dedicated studies
Hepatic function, cardiovascular disease, and seizure disorders as exclusions in the COMP360 pharmacokinetic study
Pregnancy and breastfeeding
Psychiatric and treatment-history exclusions in the phase 3 trials
“Prior or ongoing bipolar disorder, any psychotic disorder, including schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder (unless substance induced or due to a medical condition), antisocial personality disorder as assessed by a structured clinical interview (MINI 7.0.2)” (opens the source at this quote in a new tab)
“Borderline personality disorder as demonstrated by medical history or the Mini International Neuropsychiatric Interview Plus (MINI plus) - borderline personality disorder module” (opens the source at this quote in a new tab)
“Ongoing post-traumatic stress disorder, obsessive-compulsive disorder, or anorexia nervosa as assessed by medical history and a structured clinical interview (MINI 7.0.2)” (opens the source at this quote in a new tab)
“Psychiatric inpatient within the past 12 months prior to Screening” (opens the source at this quote in a new tab)
“Use of electroconvulsive therapy, deep brain stimulation, or vagus nerve stimulation during the current depressive episode” (opens the source at this quote in a new tab)
Regulatory expectation for representative trial populations